
Understand how low desire, arousal and erection difficulties differ, when testosterone testing matters, and which questions to ask a clinician.

Libido is your interest in sex. Arousal is the experience of feeling sexually excited. Erectile function is the ability to get and keep an erection. These are related parts of sexual experience, but they describe different things.
The European Association of Urology (EAU) recommends assessing erection characteristics separately from concerns about desire and arousal. Its guidance also separates questions about ejaculation and orgasm. That distinction gives a clinical conversation a more precise starting point than treating every sexual change as the same problem.
This article is for informational purposes and is not medical advice. A qualified healthcare professional should interpret symptoms and laboratory results and make decisions about testing or treatment.
Sexual symptoms and testosterone results answer different questions. In its erectile dysfunction guidance, the EAU assesses desire and arousal through sexual history and evaluates erection characteristics separately. It also recommends early-morning, fasting total testosterone as part of the laboratory evaluation for men with erectile dysfunction.
The relevant numerical threshold in the EAU male-hypogonadism guideline is 12 nmol/L for late-onset hypogonadism. This is a diagnostic decision point within that guideline, not a complete laboratory reference range. It is not a score for libido or a measurement of erection quality.
A laboratory reference interval and a guideline diagnostic threshold serve different purposes. The interval gives laboratory context for a measurement. The threshold helps guide assessment for a particular condition. Neither should replace the clinical history or be treated as a universal definition of healthy sexual function.
Biologically, testosterone testing concerns a hormone rather than a direct measurement of sexual interest or erectile response. A low result raises a hormonal question. The symptom history establishes which parts of sexual function have changed and whether those changes fit the condition being considered.
For a diagnosis of hypogonadism, the EAU requires compatible symptoms or signs together with consistently low testosterone. Measurements should be taken on at least two occasions, in the morning and fasting, using a reliable assay. The guideline recommends repeating a low result before starting testosterone therapy.
The practical discussion is therefore about both the result and its meaning: how it relates to the laboratory context, whether it remains low on repeat testing and whether the symptoms support further assessment. A single number should not become a diagnosis by itself.
The clearest description starts with the function that has changed. Reduced interest in sex is different from difficulty becoming aroused. Difficulty getting or maintaining an erection is another concern, even when these experiences occur together.
Reduced desire means less interest in sex. It is useful to describe this as an interest concern rather than use “erectile dysfunction” as a label for every sexual change. The EAU includes decreased libido among the symptoms clinicians should assess when considering possible hypogonadism during an erectile dysfunction evaluation.
An important distinction is whether reduced interest occurs alone or alongside an erection problem. Discussing sexual interest separately from erection quality helps keep both concerns visible rather than allowing one label to stand in for the whole experience.
An arousal concern relates to difficulty feeling sexually excited. It deserves its own description even when interest in sex or erection quality is also part of the concern. The EAU recommendation to ask separately about arousal makes room for that distinction.
Wanting sexual activity and describing the experience of becoming aroused answer different questions. During a clinical conversation, it helps to explain which experience has changed rather than assume that “low libido” captures both. The aim is a clear account of the symptom, not a self-assigned diagnosis.
The EAU defines erectile dysfunction, or ED, as a persistent inability to attain and maintain an erection sufficient for satisfactory sexual performance. That definition concerns erectile response. It does not establish whether a man wants sex or feels mentally or physically aroused.
Describing whether the difficulty involves getting an erection or maintaining one gives the clinician more useful information than saying only that sexual function is worse. Desire and arousal should still be discussed separately. Understanding the limits of a testosterone explanation for erection problems also helps frame the assessment.
Reduced desire and erection difficulty can occur together without being identical problems. Their overlap does not settle whether they share a cause. The EAU approach supports documenting each concern and then considering the relevant medical and personal context.
It also includes questions about ejaculation and orgasm rather than treating erection quality as a complete account of sexual health. The useful clinical task is to identify the affected functions first. Possible explanations can then be assessed against that fuller history.
The EAU identifies several possible causes of ED and recognizes that more than one may contribute. Its guidance supports a broader assessment than checking testosterone alone. Relevant inputs include physiological factors, medication exposure and the psychological or relationship setting in which symptoms occur.
These categories are not competing explanations that a patient must choose between. The EAU also recognizes mixed causes. A clinical assessment can consider hormonal and nonhormonal contributors together instead of requiring the symptoms to fit a single explanation from the outset.
A medication review is particularly important to keep within qualified care. Raising the possibility of a drug-related contribution is a reason to discuss the prescription with its prescriber. It is not a reason to stop or change medication without medical advice.
The same principle applies to psychological and relationship concerns. Mentioning them does not dismiss a physical symptom or settle its cause. Understanding how medical history and personal context shape sexual assessment helps make the conversation broader and more accurate.
Treatment evidence needs to be matched to the people studied. The EAU male-hypogonadism guideline reports potential sexual-function benefits from testosterone therapy in men with hypogonadism. It does not report evidence of benefit for sexual dysfunction in men with normal testosterone.
The EAU erectile dysfunction guidance also notes that some men with hypogonadism who have not responded to PDE5 inhibitors may respond better after testosterone therapy. That finding concerns a selected clinical group. It is not evidence that testosterone is a general treatment for erection difficulties.
The same guidance allows consideration of testosterone when clinically indicated in men with low or low-normal levels and accompanying sexual concerns. “Low-normal” is not a standalone treatment instruction. Decisions belong within an assessment of symptoms and the diagnostic criteria for deficiency.
For a patient considering TRT, the useful question is which identified problem the clinician expects treatment to address. Desire and erectile response should remain distinct outcomes in that discussion. That keeps treatment expectations connected to the assessed condition rather than to a broad promise of better sexual function.
“Is my main change in desire, arousal or erectile function? Which health conditions, medications or relationship factors could contribute? Is morning fasting testosterone testing appropriate? If a result is low, how should it be repeated and interpreted? If treatment is considered, which symptom is it expected to address?”
Treating low desire and erection difficulty as the same hormone problem confuses symptoms with test results, a mistake Testostra addresses through evidence-led education. Explanations of total testosterone alongside free testosterone and SHBG help readers understand laboratory findings while preserving the distinction between learning about male hormonal health and receiving personal medical advice.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra